‘Dim light’ finds eye disease

‘Dim light’ finds eye disease

QUEENSLAND UNIVERSITY OF TECHNOLOGY

The researchers hope that this test will be used by ophthalmologists and optometrists to identify patients with a high genetic risk of developing AMD. Image: nyul/iStockphoto The leading cause of blindness in Australia, age-related macular degeneration (AMD), may be detected in healthy people at risk of developing the disease thanks to the discovery of a technique for early detection by researchers at Queensland University of Technology (QUT). Using standard clinical techniques, the detection of AMD has previously not been possible in the disease's early, or "subclinical", stages. Practitioners tend to diagnose AMD once small changes become visible at the back of a patient's eye. However, degeneration begins many years before these clinical signs appear. During a two-year research project, eye specialist Dr Beatrix Feigl from QUT's Institute of Health and Biomedical Innovation (IHBI) used a "dim light vision" test which was very sensitive to early changes in a person's vision. "We can detect subclinical visual impairment in healthy participants genetically at risk for AMD," she said. "In the future we hope this test might be utilised by ophthalmologists and optometrists to identify patients with a high genetic risk of developing AMD but without any clinical signs of the disease. This would enable specialists to advise patients on lifestyle changes which may delay disease onset and reduce its severity." Dr Feigl said that genetic pre-disposition accounted for around half the cases of AMD. However, lifestyle risk factors for AMD, which could be controlled by a patient, included poor diet, lack of exercise and smoking. "We know that lifestyle changes can decrease a person's chance of getting worse forms of the disease," she said. The number of people who could potentially benefit from this research is huge. "One in seven Australians over 50 is affected by this disease," Dr Feigl said. The next phase of Dr Feigl's research will be a longitudinal study, following up with people who took part in the study who were shown to have early changes to their vision. "We will follow them up and see if their vision deteriorates over time," she said. It is hoped that this second stage of the research will prove that the subclinical vision impairment has been an accurate predictor of AMD. Dr Feigl said that people could currently be gene tested, and lifestyle risk factors could be analysed. However, neither of these predictors alone was entirely prognostic. A clinical vision test was needed to allow a rigorous assessment of the role of both genes and lifestyle on AMD development.